ISDA

Deposition Date 2021-11-27

Release Date 2022-05-25

Last Version Date 2024-10-16

Entry Detail

PDB ID:

7QDG

Keywords:

VIRAL PROTEIN

Title:

SARS-CoV-2 S protein S:A222V + S:D614G mutant 1-up

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2 (Taxon ID: 2697049)
Escherichia virus T4 (Taxon ID: 10665)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

ELECTRON MICROSCOPY

Resolution:

3.40 Å

Aggregation State:

PARTICLE

Reconstruction Method:

SINGLE PARTICLE

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Spike glycoprotein,Fibritin
Gene (Uniprot):S, wac
Mutations:S:A222V + S:D614G
Chain IDs:A, B, C
Chain Length:1250
Number of Molecules:3
Biological Source:Severe acute respiratory syndrome coronavirus 2, Escherichia virus T4

UniProt ID:P0DTC2,P10104 Pfam ID:PF16451, PF09408, PF19209, PF01601

Ligand Molecules

NAG

Primary Citation

The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation.

Ginex, T, Marco-Marin, C, Wieczor, M, Mata, C.P, Krieger, J, Ruiz-Rodriguez, P, Lopez-Redondo, M.L, Frances-Gomez, C, Melero, R, Sanchez-Sorzano, C.O, Martinez, M, Gougeard, N, Forcada-Nadal, A, Zamora-Caballero, S, Gozalbo-Rovira, R, Sanz-Frasquet, C, Arranz, R, Bravo, J, Rubio, V, Marina, A, Geller, R, Comas, I, Gil, C, Coscolla, M, Orozco, M, Llacer, J.L, Carazo, J.M.Show

Plos Pathog. 18 e1010631 e1010631 (2022)

PMID: 35816514 DOI: 10.1371/journal.ppat.1010631

Abstact

The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has since reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness.

Legend

Protein

Chemical

Disease

Primary Citation of related structures